Search a ticker

Categories
Biotech Stocks Featured Investing Stock Market Today Stocks to Watch

5 Top Biotech Stocks To Watch In January 2022

Could these biotech stocks be poised for gains in 2022?

biotech stocks

5 Biotech Stocks For Your Mid-January 2022 Watchlist

Biotech stocks have often been a popular theme in the stock market. Even without the catalyst from the ongoing pandemic, the industry is one that many investors keep a close tab on. Now, why is that so? For starters, biotech is well-known for being a high-risk, high-reward industry. With multiple phases of trials and billions of dollars in capital at stake, the sky is often the limit for biotech stocks. Look no further than Moderna (NASDAQ: MRNA) which has grown by more than ten-fold since the onset of the pandemic. And that is thanks to the company being one of the pioneers of the coronavirus vaccine. 

That said, most companies may not get a fairy tale ending like Moderna and would likely take years to have a breakthrough, if at all. So, investors should understand what they’re looking for and the risks as well. In the current climate, the coronavirus pandemic is still a concern after two dreadful years. For instance, GlaxoSmithKline (NYSE: GSK) and Vir Biotechnology (NASDAQ: VIR) announced that they will be supplying the U.S. government an additional 600,000 doses of their monoclonal antibody, sotrovimab. With that in mind, would you put up a list of top biotech stocks to watch the stock market today?

Best Biotech Stocks To Watch In January 2022

Adagio Therapeutics

First up, we will be looking at Adagio. For those unaware, this is a clinical-stage biopharmaceutical company that specializes in antibody-based solutions for infectious diseases that have pandemic potential. Now, its primary focus is on the virus SARS-CoV-2, its variants, and the disease caused by the virus. Its lead product candidate, ADG20, has been gaining plenty of traction in the stock market lately.

For starters, the company summarized recent findings reported in three separate publications that show the drug has neutralization activity against the Omicron variant. There are also outlines concerning initiatives to address the current and future variants of concerns.

Furthermore, Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Should the drug receive authorization soon, it would be a huge boost for Adagio. All things considered, would you be jumping on the ADGI stock bandwagon?

[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know

Pacific Biosciences

Following that, we will be looking at Pacific Biosciences of California (PACB). In detail, the company specializes in sequencing systems to help scientists resolve genetically complex problems. As of now, the company has developed its Single Molecule, Real-Time (SMRT) technology. This technology enables single-molecule, real-time detection of nucleic acid sequences and addresses many of the limitations of previous sequencing technologies. 

Earlier this week, PACB along with Berry Genomics announced a collaboration to provide PACB’s long-read sequencing technology to the Chinese clinical market. Under the agreement, PACB will develop its first long-read desktop sequencing platform with funding and guidance from Berry. So, once the product is ready, Berry will purchase at least 50 systems for use and sale in China. Keeping this in mind, would you consider adding PACB stock to your watchlist?

Vertex Pharmaceuticals

Another top biotech company you should note is Vertex Pharmaceuticals. It is a company that focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF). Besides that, it is also in the midst of advancing its research and development programs in other indications. Currently, the company has several approved medicines that treat the underlying cause of CF. This includes KAFTRIO, SYMDEKO, ORKAMBI, and KALYDECO. 

Recently, there are reasons for optimism among VRTX stock investors. It announced on Tuesday that the European Commission has approved the label extension of KAFTRIO in a combination regimen with ivacaftor. This indication is for patients aged 6 through 11 years old who have at least one F508del mutation in the CF transmembrane conductance regulator gene.

Hence, this would provide more treatment options for physicians to treat this devastating disease in early life. Given this exciting development, would you consider VRTX stock a top biotech stock to watch right now?

[Read More] Best Monthly Dividend Stocks To Buy Now? 5 For Your List

BioNTech

BioNTech is a Germany-based clinical-stage biotechnology company. Essentially, it focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. In addition, the company also develops a broad product pipeline using different scientific approaches and technology platforms.

Well, BNTX stock is yet another vaccine company that has benefited greatly from the pandemic. More than doubling its value over the past year, some still see it as one of the top picks in the biotech industry. 

Last week, the company and InstaDeep Ltd announced the development of a new computational method. It can analyze worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2. By combining structural modeling of the viral Spike protein and AI algorithms, it can flag potentially high-risk variants entered into SARS-CoV-2 sequence data repositories within less than a day. In a pandemic where a new variant emerges ever so often, this new development would be a welcome addition. With that said, would you consider investing in the future of BNTX stock?

[Read More] Best Artificial Intelligence Stocks To Buy Right Now? 5 To Watch

Novavax

Last but not least, we have the clinical-stage biotech company, Novavax. Put simply, the company specializes in recombinant nanoparticle vaccines and adjuvants. By leveraging its recombinant nanoparticle vaccine technology, it produces vaccine candidates to respond to both known and newly emerging diseases.

With Omicron running wild right now, NVAX stock is often under the limelight among investors. Despite waiting for its vaccine to be authorized in the U.S., it already made its mark in three major markets globally. The company CEO, Stanley Erck, claims that the company is “going to make a significant impact on this Covid pandemic”. 

Yesterday, Novavax and SK Bioscience announced that South Korea’s Ministry of Food and Drug Safety has approved a Biologics License Application (BLA) from SK Bioscience for Nuvaxovid™ COVID-19 Vaccine. The vaccine is indicated for active immunization in individuals 18 years of age and older to prevent COVID-19. Slowly, but surely, the company’s coronavirus vaccine is seeing adoption in more countries around the world. With that said, should you be eyeing NVAX stock?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

By Jonathan Phillip

Jonathan Phillip is an up and coming financial contributor in the stock market today. He's found a strong niche in writing about true growth industries. His main focus for the last 5 years has been on the cannabis industry and marijuana stocks. He is one of the top contributors to cannabis media outlets like MarijuanaStocks.com. He also is head of social media management for StockMarket.com.

Since an early age, Jonathan has been an active member of the cannabis culture. Coming from Miami, Florida, he's been able to identify emerging trends in the space including the emergence of cannabis derivatives, vapes, e-liquids, wax, and more. His ability to identify emerging niches has afforded him the ability to source valuable information from top industry names.

Jonathan has also managed to build a strong social media presence for companies. He has worked with hundreds of public companies to develop a digital presence. As an active blogger and social media influencer, his focus is on lifestyle segments of the market. You can find Jonathan reporting on anything from industry conferences and investor events to corporate disclosures and cannabis market movers.

Since the early days of marijuana companies going public, Jonathan has made it a point to find information before the crowd. The main target of his writing is on undiscovered or under-researched companies that could hold true, lasting market potential. Through his research, Jonathan has managed to be one of the early writers to identify the opportunity of cannabis over other things like alcohol and he was one of the first reporters to cover the multi-billion dollar deals that materialized in 2017 and 2018. He has also covered the emergence of multi-state operators in the U.S. after Canada paved the way in late 2018 and 2019 for legalization in North America.

Jonathan is also an active member of the underground hip-hop scene. He has worked with some of the biggest names in the rap community while also gaining valuable insight from top producers and business moguls focused on moving brands forward. In his free time, Jonathan builds social communities and continues to hone his skills as a leading financial writer.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments